Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER)

Saskia Antwerpes, Marie Costa, Marion Coste, Morgane Bureau, Gwenaelle Maradan, Christophe Cutarella, Jacques Leloutre, Olivier Riccobono-Soulier, Sophie Hedoire, Elodie Frot, Fabienne Vernier, Stéphanie Vassas-Goyard, Tangui Barré, Danielle Casanova, Patrizia Carrieri, Saskia Antwerpes, Marie Costa, Marion Coste, Morgane Bureau, Gwenaelle Maradan, Christophe Cutarella, Jacques Leloutre, Olivier Riccobono-Soulier, Sophie Hedoire, Elodie Frot, Fabienne Vernier, Stéphanie Vassas-Goyard, Tangui Barré, Danielle Casanova, Patrizia Carrieri

Abstract

Background: ETHER ("Education THEérapeutique pour la Réduction des dommages en alcoologie" or Therapeutic education for alcohol-related harm reduction) is a multicentre community-based mixed-methods study, which aims to evaluate the effectiveness of the innovative therapeutic patient education (TPE) programme 'Choizitaconso' in a sample of French people with alcohol use disorder (people with AUD). Choizitaconso teaches people with AUD psychosocial skills to help them (re)establish controlled drinking and reduce alcohol-related harms. Recruitment started in October 2019. We present here the protocol of the ETHER study.

Methods: ETHER's quantitative component involves a 6-month controlled intervention study which evaluates Choizitaconso's effectiveness by comparing 30 people with AUD following the programme with a control group of 60 people with AUD not enrolled in it, using a questionnaire co-constructed by the research team and members of the people with AUD community. Thirty-four alcohol-related harms are assessed and summed to provide an individual measure of the 'harm burden' from consuming alcohol (primary outcome). Secondary outcomes are anticipated and internalized stigma, alcohol consumption measures, craving for alcohol, coping strategies, health-related quality of life, self-confidence to control or abstain from drinking, treatment self-regulation, anxiety and depressive symptoms, alcohol-related neuropsychological impairments, and capabilities (a measure of wellbeing in adults). Data will be collected in face-to-face and phone-based interviews at enrolment and 6 months later. Linear regression models will be used to assess the impact of the TPE programme on changes in the primary and secondary outcomes, while adjusting for other correlates and confounders. The study's qualitative component comprises semi-structured interviews with 16 people with AUD who have already completed the TPE programme at least 6 months before the interview. Qualitative interviews will be analysed using thematic analysis.

Results and conclusions: ETHER is the first evaluation study of an innovative TPE programme specifically designed to reduce alcohol-related harms and reach controlled drinking in France. The involvement of the people with AUD community in selecting which experienced and perceived alcohol-related harms to measure ensures that ETHER will provide healthcare staff and researchers with a relevant set of harm reduction criteria for use in future research. Finally, ETHER will provide scientific justification for implementing novel alcohol-related harm reduction approaches and champion controlled drinking as a therapeutic goal. Trial registration ClinicalTrials.gov, NCT03954054. Registered 17 May 2019-Prospectively registered, https://ichgcp.net/clinical-trials-registry/NCT03954054?cond=alcohol&cntry=FR&city=Marseille&draw=1&rank=1 .

Keywords: Abstinence; Alcohol; Community-based participatory research; Controlled drinking; Harm reduction; Health-related quality of life; Patient education; Psychosocial skills.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
TPE programme presentation
Fig. 2
Fig. 2
ETHER: general study design. Abbreviations: TPE: Therapeutic patient education
Fig. 3
Fig. 3
Participant timeline

References

    1. Bonaldi C, Hill C. LA MORTALITÉ ATTRIBUABLE À L’ALCOOL EN FRANCE EN 2015: 11.
    1. Kopp P, Ogrodnik M. The social cost of drugs in France in 2010. Eur J Health Econ. 2017;18(7):883–892. doi: 10.1007/s10198-016-0835-9.
    1. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010;376(9752):1558–1565. doi: 10.1016/S0140-6736(10)61462-6.
    1. World Health Organization, World Health Organization, World Health Organization, Management of Substance Abuse Team. Global status report on alcohol and health 2018. 2018.
    1. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815–824. doi: 10.1001/jama.2018.11406.
    1. Dawson DA, Smith SM, Saha TD, Rubinsky AD, Grant BF. Comparative performance of the AUDIT-C in screening for DSM-IV and DSM-5 alcohol use disorders. Drug Alcohol Depend. 2012;126(3):384–388. doi: 10.1016/j.drugalcdep.2012.05.029.
    1. Bernardin F, Maheut-Bosser A, Paille F. Cognitive impairments in alcohol-dependent subjects. Front Psychiatry. 2014 doi: 10.3389/fpsyt.2014.00078/abstract.
    1. Zgierska AE, Miller MM, Rabago DP, Hilliard F, McCarthy P, Cowan P, et al. Language matters: it is time we change how we talk about addiction and its treatment. J Addict Med. 2021;15(1):10–12. doi: 10.1097/ADM.0000000000000674.
    1. Ray LA, Bujarski S, Grodin E, Hartwell E, Green R, Venegas A, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45(2):124–140. doi: 10.1080/00952990.2018.1528265.
    1. Good Practice recommendation - Alcohol misuse: screening,diagnosis and treatment | cesp [Internet]. [cité 6 juill 2020]. Disponible sur:
    1. Kaner EF, Beyer FR, Muirhead C, Campbell F, Pienaar ED, Bertholet N, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2018 doi: 10.1002/14651858.CD004148.pub4/full.
    1. Raistrick D, Heather N, Godfrey C. A Review of the Effectiveness of Treatment for Alcohol Problems. The National Treatment Agency for Substance Misuse. 2006;
    1. Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol. 2006;26(Suppl 1):S37–42. doi: 10.1097/01.jcp.0000248604.58305.b3.
    1. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56(8):719–724. doi: 10.1001/archpsyc.56.8.719.
    1. Irvin JE, Bowers CA, Dunn ME, Wang MC. Efficacy of relapse prevention: a meta-analytic review. J Consult Clin Psychol. 1999;67(4):563–570. doi: 10.1037/0022-006X.67.4.563.
    1. Feeney GFX, Young RMD, Connor JP, Tucker J, McPherson A. Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved? Aust N Z J Psychiatry. 2002;36(5):622–628. doi: 10.1046/j.1440-1614.2002.01019.x.
    1. Constant A, Sherlaw W, Kovess-Masfety V. Seeking mental health care from private health practitioners among individuals with alcohol dependence/abuse; results from a study in the French general population. Alcohol. 2017;59:1–6. doi: 10.1016/j.alcohol.2016.09.028.
    1. Font H, Roelandt J-L, Behal H, Geoffroy P-A, Pignon B, Amad A, et al. Prevalence and predictors of no lifetime utilization of mental health treatment among people with mental disorders in France: findings from the ‘Mental Health in General Population’ (MHGP) survey. Soc Psychiatry Psychiatr Epidemiol. 2018;53(6):567–576. doi: 10.1007/s00127-018-1507-0.
    1. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiat. 2015;72(8):757–766. doi: 10.1001/jamapsychiatry.2015.0584.
    1. Probst C, Manthey J, Martinez A, Rehm J. Alcohol use disorder severity and reported reasons not to seek treatment: a cross-sectional study in European primary care practices. Substance Abuse Treat Prevent Policy. 2015;10(1):32. doi: 10.1186/s13011-015-0028-z.
    1. Marlatt GA, Witkiewitz K. Harm reduction approaches to alcohol use: Health promotion, prevention, and treatment. Addict Behav. 2002;20:867–886. doi: 10.1016/S0306-4603(02)00294-0.
    1. Charlet K, Heinz A. Harm reduction -a systematic review on effects of alcohol reduction on physical and mental symptoms: Effects of alcohol reduction. Addict Biol. 2017;22(5):1119–1159. doi: 10.1111/adb.12414.
    1. Kouimtsidis C, Duka T, Palmer E, Lingford-Hughes A. Prehabilitation in alcohol dependence as a treatment model for sustainable outcomes. A narrative review of literature on the risks associated with detoxification, from animal models to human translational research. Front Psychiatry. 2019;10:339. doi: 10.3389/fpsyt.2019.00339.
    1. Henssler J, Müller M, Carreira H, Bschor T, Heinz A, Baethge C. Controlled drinking—non-abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-analysis and meta-regression. Addiction. 2021;116(8):1973–1987. doi: 10.1111/add.15329.
    1. World Health Organization. Regional Office for Europe. Therapeutic patient education: continuing education programmes for health care providers in the field of prevention of chronic diseases : report of a WHO working group [Internet]. Copenhagen: Copenhagen : WHO Regional Office for Europe; 1998 [cité 7 nov 2018]. Report No.: EUR/ICP/QCPH 01 01 03 Rev.2. Disponible sur:
    1. Hoving C, Visser A, Mullen PD, van den Borne B. A history of patient education by health professionals in Europe and North America: From authority to shared decision making education. Patient Educ Couns. 2010;78(3):275–281. doi: 10.1016/j.pec.2010.01.015.
    1. Éducation thérapeutique du patient Définition finalités et organisation: Juin 2007. Obésité. 2009;4(1):39–43. doi: 10.1007/s11690-009-0174-4.
    1. Lagger G, Pataky Z, Golay A. Efficacy of therapeutic patient education in chronic diseases and obesity. Patient Educ Couns. 2010;79(3):283–286. doi: 10.1016/j.pec.2010.03.015.
    1. Lian J, McGhee SM, So C, Chau J, Wong CKH, Wong WCW, et al. Long-term cost-effectiveness of a patient empowerment programme for type 2 diabetes mellitus in primary care. Diabetes Obes Metab. 2019;21(1):73–83. doi: 10.1111/dom.13485.
    1. Albano MG, Deccache A, Godibile A, d’Ivernois J-F. Development of publications on patient education in chronic diseases from 1999 to 2009. Educ Ther Patient/Ther Patient Educ. 2009;1(2):S101–S107. doi: 10.1051/tpe/2009014.
    1. Guillemot S. Place et apports de l’éducation thérapeutique du patient en addictologie/tabacologie. Rev Mal Respir Actual. 2014;6(3):248–252.
    1. Pauly BB, Vallance K, Wettlaufer A, Chow C, Brown R, Evans J, et al. Community managed alcohol programs in Canada: Overview of key dimensions and implementation. Drug Alcohol Rev. 2018;37(Suppl 1):S132–S139. doi: 10.1111/dar.12681.
    1. Stockwell T, Zhao J, Pauly B, Chow C, Vallance K, Wettlaufer A, et al. Trajectories of alcohol use and related harms for managed alcohol program participants over 12 months compared with local controls: a quasi-experimental study. Alcohol Alcohol. 2021;56(6):651–659. doi: 10.1093/alcalc/agaa134.
    1. Favrod-Coune T, Aebischer G, Grondin-Giletti F, Girod I, Simoneau H, Broers B. “Alcochoix+”: controlled drinking within a structured programme—a cohort study in Switzerland. Swiss Med Week. 2019;149:w20120.
    1. Körkel J, Schellberg B, Haberacker K, Langguth W, Neu B. The Outpatient Group Treatment Program for Controlled Drinking. :6.
    1. Koerkel J. Behavioural self-management with problem drinkers: One-year follow-up of a controlled drinking group treatment approach. Addict Res Theory. 2006;14(1):35–49. doi: 10.1080/16066350500489253.
    1. Casanova D, Cruz CGD, Hourrier K, Riccobono-Soulier O, Seguin J, Vassas S. Choizitaconso©. Un apport à la réduction des dommages en alcoologie. Alcoologie et Addictologie. 2018;40(4):334–339.
    1. on behalf of the GrandStand, Safe Step and Teenage Girls on the Move Research Groups, Leask CF, Sandlund M, Skelton DA, Altenburg TM, Cardon G, et al. Framework, principles and recommendations for utilising participatory methodologies in the co-creation and evaluation of public health interventions. Res Involv Engagem. 2019;5(1):2.
    1. Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. The Lancet. 2021 doi: 10.1016/S0140-6736(21)01701-3.
    1. Bush K. The AUDIT alcohol consumption questions (AUDIT-C) an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789. doi: 10.1001/archinte.158.16.1789.
    1. Hagaman AK, Wutich A. How Many Interviews Are Enough to Identify Metathemes in Multisited and Cross-cultural Research? Another Perspective on Guest, Bunce, and Johnson’s (2006) Landmark Study. Field Methods. 2017;29(1):23–41. doi: 10.1177/1525822X16640447.
    1. Paillé P, Mucchielli A. Chapitre 11 - L’analyse thématique. U. 2012;231‑314.
    1. Structuration d’un programme d’éducation thérapeutique du patient dans le champ des maladies chroniques [Internet]. Haute Autorité de Santé. [cité 6 juill 2020]. Disponible sur:
    1. Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state of the science and challenges for research. Addiction. 2003;98:1–12. doi: 10.1046/j.1359-6357.2003.00586.x.
    1. Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO. Substance use stigma: Reliability and validity of a theory-based scale for substance-using populations. Drug Alcohol Depend. 2016;162:34–43. doi: 10.1016/j.drugalcdep.2016.02.019.
    1. Muller L, Spitz E. Évaluation multidimensionnelle du coping : validation du Brief COPE sur une population française. 2003;12.
    1. Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries: Results from the IQOLA Project. 8.
    1. Breslin FC, Sobell LC, Sobell MB, Agrawal S. A comparison of a brief and long version of the Situational Con®dence Questionnaire. Behaviour Research and Therapy. 2000;10.
    1. Williams GC, Freedman ZR, Deci EL. Supporting autonomy to motivate patients with diabetes for glucose control. Diabetes Care. 1998;21(10):1644–1651. doi: 10.2337/diacare.21.10.1644.
    1. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Ritz L, Lannuzel C, Boudehent C, Vabret F, Bordas N, Segobin S, et al. Validation of a brief screening tool for alcohol-related neuropsychological impairments. Alcohol: Clin Exp Res. 2015;39(11):2249–2260. doi: 10.1111/acer.12888.
    1. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167–176. doi: 10.1007/s11136-011-9927-2.
    1. Miller WR, Tonigan JS, Longabaugh R. The Drinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse : test manual [Internet]. NIH Publication. 1995. (Project MATCH Monograph Series). Disponible sur:
    1. Dawson DA, Room R. Towards agreement on ways to measure and report drinking patterns and alcohol-related problems in adult general population surveys: the Skarpö conference overview. J Subst Abuse. 2000;12(1–2):1–21. doi: 10.1016/S0899-3289(00)00037-7.
    1. Wyllie A, Zhang JF, Casswell S. Risk functions for frequency of alcohol-related negative consequences: New Zealand survey data. Addiction. 2000;95(12):1821–1832. doi: 10.1046/j.1360-0443.2000.9512182111.x.
    1. Zanello A, Weber Rouget B, Gex-Fabry M, Maercker A, Guimon J. Validation du Questionnaire de fonctionnement social (QFS), un autoquestionnaire mesurant la fréquence et la satisfaction des comportements sociaux d’une population adulte psychiatrique. L’Encéphale. 2006;32(1):45–59. doi: 10.1016/S0013-7006(06)76136-X.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera